Growing opposition to vaccines in the U.S., driven by recent government policy changes, makes it difficult to see a return on investment in vaccine development, Moderna CEO Stéphane Bancel said this week.
Moderna Won’t Run Phase III Vaccine Trials as Skepticism Grows in US: Bloomberg